Time trends for alendronate prescription practices in women with chronic obstructive pulmonary disease and women exposed to systemic glucocorticoids

Osteoporosis International

Volumn 24, Issue 6, 2013, Pages 1891-1897

  Brask Lindemann, D ^a   Eiken, P ^b   Eskildsen, P ^a   Abrahamsen, B ^c  

^a Mental Health Services CPH   (Denmark)

^b HILLERØD HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Alendronate; Chronic obstructive pulmonary disease; Drug prescription; Glucocorticoids; Osteoporosis; Time Factors

Indexed keywords

ALENDRONIC ACID; GLUCOCORTICOID;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; DISEASE ASSOCIATION; DRUG EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; CASE-CONTROL STUDIES; DENMARK; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; GLUCOCORTICOIDS; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PHYSICIAN'S PRACTICE PATTERNS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGISTRIES; RISK FACTORS;

EID: 84878788347     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-012-2220-6     Document Type: Article

References (28)

1. Franco CB, Paz-Filho G, Gomes PE, Nascimento VB, Kulak CA, Boguszewski CL, Borba VZ (2009) Chronic obstructive pulmonary disease is associated with osteoporosis and low levels of vitamin D. Osteoporos Int 20:1881-1887
2. Gluck O, Colice G (2004) Recognizing and treating glucocorticoid-induced osteoporosis in patients with pulmonary diseases. Chest 125:1859-1876
3. Maggi S, Siviero P, Gonnelli S, Schiraldi C, Malavolta N, Nuti R, Crepaldi G (2009) Osteoporosis risk in patients with chronic obstructive pulmonary disease: the EOLO study. J Clin Densitom 12:345-352
4. Majumdar SR, Villa-Roel C, Lyons KJ, Rowe BH (2010) Prevalence and predictors of vertebral fracture in patients with chronic obstructive pulmonary disease. Respir Med 104:260-266
5. The Asia Pacific COPD Roundtable Group (2005) Global Initiative for Chronic Obstructive Lung Disease strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: an Asia-Pacific perspective. Respirology 10:9-17
6. Huertas A, Palange P (2011) COPD: a multifactorial systemic disease. Ther Adv Respir Dis 5:217-224
7. Graat-Verboom L, van den Borne BE, Smeenk FW, Spruit MA, Wouters EF (2011) Osteoporosis in COPD outpatients based on bone mineral density and vertebral fractures. J Bone Miner Res 26:561-568
8. Barnes PJ, Celli BR (2009) Systemic manifestations and comorbidities of COPD. Eur Respir J 33:1165-1185
9. Papaioannou A, Parkinson W, Ferko N, Probyn L, Ioannidis G, Jurriaans E, Cox G, Cook RJ, Kumbhare D, Adachi JD (2003) Prevalence of vertebral fractures among patients with chronic obstructive pulmonary disease in Canada. Osteoporos Int 14:913-917
10. Lange P (2009) Chronic obstructive pulmonary disease and risk of infection. Pneumonol Alergol Pol 77:284-288
11. Lane NE, Lukert B (1998) The science and therapy of glucocorticoid- induced bone loss. Endocrinol Metab Clin North Am 27:465-483
12. Reid IR (1997) Glucocorticoid osteoporosis - mechanisms and management. Eur J Endocrinol 137:209-217
13. Sambrook P, Lane NE (2001) Corticosteroid osteoporosis. Best Pract Res Clin Rheumatol 15:401-413
14. van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777-787
15. Cooper MS (2004) Sensitivity of bone to glucocorticoids. Clin Sci (Lond) 107:111-123
16. Grossman JM, Gordon R, Ranganath VK et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 62:1515-1526
17. DKMS (2010) Vejledning til udredning og behandling af osteoporose. http://www.dkms.dk/vejledning/11-glukokort.htm. Accessed 24 Jan 2012
18. Rabinovich RA, MacNee W (2011) Chronic obstructive pulmonary disease and its comorbidities. Br J Hosp Med (Lond) 72:137-145
19. Smith BJ, Laslett LL, Pile KD, Phillips PJ, Phillipov G, Evans SM, Esterman AJ, Berry JG (2004) Randomized controlled trial of alendronate in airways disease and low bone mineral density. Chron Respir Dis 1:131-137
20. Madsen H, Brixen K, Hallas J (2010) Screening, prevention and treatment of osteoporosis in patients with chronic obstructive pulmonary disease - a population-based database study. Clin Respir J 4:22-29
21. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383
22. Ferguson GT, Calverley PM, Anderson JA, Jenkins CR, Jones PW, Willits LR, Yates JC, Vestbo J, Celli B (2009) Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest 136:1456-1465
23. Jorgensen NR, Schwarz P, Holme I, Henriksen BM, Petersen LJ, Backer V (2007) The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. Respir Med 101:177-185
24. Silva DR, Coelho AC, Dumke A, Valentini JD, de Nunes JN, Stefani CL, Mendes LF, Knorst MM (2011) Prevalence and associated factors of osteoporosis among patients with chronic obstructive pulmonary disease: a cross-sectional study. Respir Care. doi: 10.4187/respcare.01056
25. Vaquero-Barrios JM, Arenas-de Larriva MS, Redel-Montero J, Bujalance-Cabrera C, Santos-Luna F, Moreno-Casado P, Espinosa-Jimenez D (2010) Bone mineral density in patients with chronic obstructive pulmonary disease who are candidates for lung transplant. Transplant Proc 42:3020-3022
26. Compston J (2010) Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol 6:82-88
27. Lukert BP, Raisz LG (1990) Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 112:352-364
28. Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L, Mosekilde L (2010) Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism. Osteoporos Int 21:1591-1597